|2.||Neuroleptic Malignant Syndrome
|3.||Heat Stroke (Heatstroke)
|4.||Muscular Diseases (Myopathy)
|1.||Roewer, Norbert: 21 articles (10/2015 - 05/2002)|
|2.||Schuster, Frank: 21 articles (03/2015 - 06/2005)|
|3.||Pessah, Isaac N: 17 articles (03/2013 - 07/2003)|
|4.||Anetseder, Martin: 16 articles (10/2015 - 05/2002)|
|5.||Dirksen, Robert T: 16 articles (09/2015 - 10/2004)|
|6.||Wappler, Frank: 16 articles (06/2015 - 08/2002)|
|7.||Brandom, Barbara W: 15 articles (12/2014 - 11/2002)|
|8.||Allen, Paul D: 15 articles (03/2013 - 07/2003)|
|9.||Treves, Susan: 13 articles (08/2013 - 10/2004)|
|10.||Hamilton, Susan L: 12 articles (09/2013 - 08/2004)|
|1.||Dantrolene (Dantrium)FDA LinkGeneric
12/01/2005 - "Dantrolene is the only drug proven effective for prevention and treatment of malignant hyperthermia (MH). "
01/01/1980 - "Dantrolene, a skeletal muscle relaxant, has been proven prophylactic and therapeutic for malignant hyperthermia (MH) in swine. "
03/01/2008 - "Dantrolene sodium, the only drug effective for treatment of malignant hyperthermia, has low water solubility that makes its clinical use difficult. "
03/01/2001 - "Dantrolene is the only known effective treatment for malignant hyperthermia. "
10/01/1998 - "Dantrolene is the only known effective treatment for malignant hyperthermia. "
|2.||Halothane (Fluothane)FDA Link
07/18/1998 - "The delayed onset of malignant hyperthermia after delivery of halothane is unusual and for successful treatment careful monitoring and rapid and aggressive therapy are needed."
08/01/1993 - "Metabolic response to halothane in piglets susceptible to malignant hyperthermia: an in vivo 31P-NMR study."
01/01/1991 - "[Malignant hyperthermia: halothane kinetics in a study model of muscular contraction. "
10/01/1990 - "In the present study cerebral blood flow (CBF) and spontaneous electroencephalogram (EEG) were recorded in 8 pigs susceptible (MHS) for the development of malignant hyperthermia and 8 non-susceptible pigs (nMHS) after exposure to 1% halothane. "
12/01/1983 - "The results of these studies do not support a use of halothane-induced aggregation of platelets to detect an abnormality in individuals susceptible to malignant hyperthermia, but do provide new evidence of the effects of halothane on cellular function."
|3.||Caffeine (No Doz)FDA LinkGeneric
10/01/2015 - "Effect of caffeine on intrinsic mechanical properties of normal and malignant hyperthermia-susceptible muscle."
03/01/2005 - "Enhanced response to caffeine and 4-chloro-m-cresol in malignant hyperthermia-susceptible muscle is related in part to chronically elevated resting [Ca2+]i."
04/01/2004 - "Enhanced sensitivity to caffeine is part of the standard tests for susceptibility to malignant hyperthermia (MH) in humans and pigs. "
09/01/2003 - "Caffeine impairs intramuscular energy balance in patients susceptible to malignant hyperthermia."
05/04/2002 - "We measured pCO(2) in the rectus femoris muscle during local stimulation with 500 microL caffeine 80 mmol/L in 12 patients susceptible to malignant hyperthermia, eight non-susceptible individuals, and seven healthy controls. "
|4.||sevoflurane (Ultane)FDA LinkGeneric
09/01/2007 - "Delayed onset of sevoflurane-induced juvenile malignant hyperthermia after second exposure."
10/01/2013 - "Sevoflurane is a known triggering agent of malignant hyperthermia (MH). "
01/01/2013 - "A minimal-invasive metabolic test detects malignant hyperthermia susceptibility in a patient after sevoflurane-induced metabolic crisis."
01/01/2013 - "In this case report, we present a case of delayed onset malignant hyperthermia-like reaction after the second exposure to sevoflurane. "
01/01/2013 - "Delayed onset malignant hyperthermia after sevoflurane."
|5.||desflurane (I 653)FDA Link
01/01/2003 - "Animal-experimental studies demonstrate desflurane's trigger effect for malignant hyperthermia (MH). "
07/01/2003 - "Is desflurane a "weak" trigger of malignant hyperthermia?"
02/01/2001 - "[Malignant hyperthermia in a pig anesthesized with desflurane]."
04/01/1998 - "A case of suspected malignant hyperthermia during desflurane administration."
08/01/1997 - "A case of suspected malignant hyperthermia during desflurane administration."
09/01/2010 - "Intravenous administration of azumolene to reverse malignant hyperthermia in swine."
03/01/2008 - "Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle."
01/01/1992 - "EU 4093 decreases intracellular [Ca2+] in skeletal muscle fibers from control and malignant hyperthermia-susceptible swine."
03/01/1990 - "Azumolene reverses episodes of malignant hyperthermia in susceptible swine."
09/01/2010 - "The efficacy of intravenous (IV) administration of azumolene (Az), an analogue 30-fold more soluble than dantrolene, on pigs susceptible to malignant hyperthermia (MH) is incompletely understood. "
|7.||Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA
03/01/1999 - "Some genetic studies have shown a linkage between malignant hyperthermia susceptibility (MHS) and chromosome 19q or the skeletal muscle ryanodine receptor (RYR1) gene. "
03/01/1994 - "Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies."
02/24/1992 - "In this study we describe the isolation of genomic clones of the 5' region of the porcine ryanodine receptor gene, a candidate for malignant hyperthermia in pigs and humans. "
11/01/1991 - "A study of the inheritance of malignant hyperthermia (MH) in the British Landrace breed revealed the same substitution of T for C at nucleotide 1843 in the ryanodine receptor (RYR1) gene that was previously shown to be correlated with MG in five Canadian swine breeds. "
12/01/2015 - "It is important to identify children who are candidates for ophthalmic surgery who might harbor RYR1 mutations because intraoperative malignant hyperthermia is potentially lethal. "
|8.||Succinylcholine (Suxamethonium Chloride)FDA LinkGeneric
07/01/1994 - "The purpose of this study was to gain new insights in the role of succinylcholine in the initiation of malignant hyperthermia (MH). "
12/01/1993 - "The agonist actions of succinylcholine (SCh) have recently come under study because of their involvement in the clinical problem of masseter muscle rigidity, and their possible involvement in malignant hyperthermia. "
11/01/1973 - "Porcine malignant hyperthermia: a study on the triggering effects of succinylcholine."
01/01/2014 - "While the impact of volatile anaesthetics to induce malignant hyperthermia (MH) is abundantly clear, the role of succinylcholine still remains controversial. "
01/01/2014 - "The effect of succinylcholine on malignant hyperthermia events in susceptible swine."
|9.||Creatine Kinase (Creatine Phosphokinase)IBA
10/01/1986 - "The validity of the bioluminescent or whole blood creatine kinase test as a screening mechanism for malignant hyperthermia was evaluated in boars in a field trial. "
07/01/1979 - "A freeze-fracture study of the plasma membrane of muscle fibres of a patient with chronic creatine kinase elevation suspected for malignant hyperthermia."
05/01/2013 - "Persistently elevated serum creatine kinase (CK) is frequently associated with predisposition to malignant hyperthermia (MH). "
06/01/2011 - "Massively increased creatine kinase levels are a strong indicator of a malignant hyperthermia reaction. "
07/01/2004 - "Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment."
09/01/2005 - "In this study we evaluated the in vitro effects of 4-chloro-3-ethylphenol (CEP) using cumulative (12.5-200 micromol/L) or bolus (75 and 100 micromol/L) administrations, on muscle specimens from malignant hyperthermia (MH) susceptible and MH nonsusceptible patients, respectively. "
02/01/2002 - "In vitro effects of 4-chloro-3-ethylphenol in skeletal muscle preparations from malignant hyperthermia susceptible and normal swine."
02/01/2002 - "Contractures were significantly greater (P < 0.05) in the malignant hyperthermia-susceptible compared to the malignant hyperthermia-normal preparations in all 4-chloro-3-ethylphenol concentration steps from 50 micromol L(-1) to 200 micromol L(-1). "
02/01/2002 - "The purpose of this study was to investigate the ability of 4-chloro-3-ethylphenol to distinguish between malignant hyperthermia-susceptible and malignant hyperthermia-normal porcine muscle specimen in the in vitro contracture test. "
09/01/2005 - "Cumulative and bolus in vitro contracture testing with 4-chloro-3-ethylphenol in malignant hyperthermia positive and negative human skeletal muscles."
06/01/2015 - "Although risk stratification studies involving large study populations were most commonly reported, AIMS were also used to report a rare life-threatening anesthesia-related complication, malignant hyperthermia. "
02/01/2006 - "In this prospective, controlled study we compared the ability of anesthesia residents to diagnose and treat a simulated malignant hyperthermia (MH) scenario with and without the ability to use the On-Line Electronic Help (OLEH) information system or any other written guidelines. "
11/01/2005 - "This case report showed an incidence of malignant hyperthermia of approximated 1:150,000 in Thai Anesthesia Incidents Study (THAI Study)."
11/01/2005 - "Malignant hyperthermia: a case report in Thai Anesthesia Incidents Study (THAI Study)."
09/01/2015 - "A Malignant Hyperthermia susceptible (MHS) patient should be anesthetized with trigger-free anesthesia. "
12/01/1980 - "A study of core temperature monitoring during general anesthesia indicates that this can be introduced as a routine procedure in order to reduce mortality from malignant hyperpyrexia. "
06/01/2014 - "Malignant hyperthermia (MH) is a rare hypermetabolic syndrome of the skeletal muscle and a potentially fatal complication of general anesthesia. "
01/01/2014 - "Malignant hyperthermia (MH) is a rare but potentially fatal complication that may develop under general anesthesia (GA) and is rarely reported in elderly patients. "
01/01/2014 - "Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by life-threatening metabolic crises during general anesthesia. "
06/01/2012 - "The use of general anesthesia in patients with SJS is dangerous, as there is a risk of malignant hyperthermia. "
|3.||Ambulatory Surgical Procedures (Outpatient Surgery)
06/01/2014 - "Malignant hyperthermia in the ambulatory surgery center: how should we prepare?"
01/01/2012 - "Special article: Creation of a guide for the transfer of care of the malignant hyperthermia patient from ambulatory surgery centers to receiving hospital facilities."
12/01/2009 - "Ambulatory surgery and malignant hyperthermia."
10/01/2004 - "Patients with malignant hyperthermia may undergo outpatient surgery but require four hours of postoperative temperature monitoring. "
10/01/1998 - "Malignant hyperthermia: considerations for ambulatory surgery."
12/01/2007 - "We describe a case of malignant hyperthermia during orthotopic liver transplantation. "
11/01/2005 - "Orthotopic liver transplantation in a malignant hyperthermia susceptible patient."
03/01/2004 - "We report on a 25-year old ASA physical status I patient, who developed within 20 minutes a full-blown malignant hyperthermia (MH) in the context of a living donor liver transplantation after 180 minutes of uneventful anaesthesia. "
05/01/1986 - "[Malignant hyperthermia during heterotopic orthotopic liver transplantation]."
03/01/2004 - "[Delayed onset of malignant hyperthermia crisis during a living donor liver transplantation caused by sevoflurane]."
05/01/1976 - "A possible means of rapid cooling in the emergency treatment of malignant hyperpyrexia."
07/01/1974 - "A pack for the emergency treatment of malignant hyperpyrexia."
05/01/1976 - "Since peritoneal dialysis is, technically, a very quick and simple procedure, it is suggested that it might play a very useful role in the emergency treatment of malignant hyperpyrexia. "
05/01/1976 - "A possible means of rapid cooling in the emergency treatment of malignant hyperpyrexia, peritoneal dialysis using a cold dialysate, is described. "
10/20/1975 - "[First-aid box for emergency treatment of malignant hyperthermia]."